PRNewsWire
01 Jan 2026, 14:18 UTC · 39w ago
Impact · against what's priced in
The article serves as a reminder of an existing class action lawsuit and previously disclosed trial failures, providing no new material catalysts. The stock's valuation has already adjusted for the 60% price drop following the Phase 2a failure of nimacimab.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Phase 2a CBeyond study of nimacimab monotherapy failed to achieve its primary endpoint of weight loss compared to placebo.
So whatFailure of a primary clinical endpoint for a lead drug candidate typically suggests a loss of commercial viability and destroys fundamental valuation.
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed against Skye Biosciences alleging that executives made false or misleading statements regarding nimacimab's effectiveness.
Continue reading
5 related stories
The article reminds investors of a January 16, 2026, deadline to seek lead plaintiff status in a lawsuit following a 60% stock price drop triggered by the failure of nimacimab to meet its primary weight loss endpoint.
Read from the article alone
Scored by the NIS engine · methodology.
More negative than 91% of claims this week
Preliminary pharmacokinetic analysis indicated lower than expected drug exposure, suggesting a potential need for higher dosing.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a federal securities class action lawsuit following a 60% stock price drop after a failed Phase 2a clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
42m ago
−73.0%
Price agrees with the score
$1.62 vs $6.00 close before publication (Dec 31) · not market-adjusted
SKYE chart →
